Figure 7 | Scientific Reports

Figure 7

From: CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway

Figure 7

Intracolonic mevalonate administration reversed the anti-fibrogenic effect of CSA13 in TNBS-treated mice. TNBS-treated mice were treated with oral-Eudragit (10 mg/kg) and/or intracolonic mevalonate (10 mg/kg) daily during the last week of experiment. (A) H&E staining. (B) Masson Trichrome staining. (C) Histology score. (D) Fibrosis score. (E) Colonic mRNA expression. 6 mice per group.

Back to article page